Why the study?
Does isolated heart transplantation lead to acceptable survival and renal outcomes in nondialysis patients with severe pretransplant renal impairment (eGFR <30 mL/min/1.73 m2)?
Does isolated heart transplantation lead to acceptable survival and renal outcomes in nondialysis patients with severe pretransplant renal impairment (eGFR <30 mL/min/1.73 m2)?
Answers are grounded in this paper and cite their sources.
Isolated heart transplantation in patients with severe pretransplant renal impairment (eGFR <30) is associated with excellent survival and low rates of progression to ESKD, suggesting many do not require simultaneous heart-kidney transplantation.
Patients with chronic heart failure referred for heart transplantation commonly have coexistent renal impairment. The question for the assessing cardiologist is to what extent the renal impairment is secondary to the heart failure and hence potentially reversible after successful heart transplantation. Alternatively, is the renal impairment due to intrinsic renal disease that is likely to worsen after the heart transplant‚ particularly when the recipient is commenced on a calcineurin inhibitor? Often‚ as in patients with diabetes, there are both reversible and irreversible factors contributing to the degree of renal impairment measured at the time of assessment. Further investigations including renal ultrasonography, estimation of proteinuria, and evaluation for renal arterial disease may be helpful in distinguishing reversible from irreversible renal dysfunction but are not always conclusive. Renal biopsy has been proposed1 but carries substantial risks‚ particularly in patients who are hemodynamically unstable or who are on long-term anticoagulation. Severe renal impairment before heart transplantation has long been recognized as a predictor of adverse outcomes after heart transplantation.2 Previous retrospective analyses of the United Network Organ Sharing (UNOS) database have investigated the impact of pretransplant renal function as assessed by estimated glomerular filtration rate (eGFR) on outcomes post–heart transplantation.3-5 In all 3 studies, eGFR determined from the most proximate blood sample taken before transplantation was associated with increased mortality and incident end-stage kidney disease (ESKD) posttransplant. In the largest review of more than 30 000 heart transplant recipients between 1988 and 2013, a pretransplant eGFR <30 mL/min/1.73 m2 was associated with a 55% increase in posttransplant mortality compared with an eGFR >90 mL/min/1.73 m2.3 The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation recommend that renal function should be assessed using eGFR or creatinine clearance “under optimal medical therapy.”6 The guidelines further recommend that “it is reasonable to consider the presence of irreversible renal dysfunction (eGFR < 30 mL/min/1.73 m2) as a relative contraindication for heart transplantation alone.”6 There are a number of implications to these statements. The first is that chronic renal dysfunction is not determined from a single measurement but rather after serial measurements with the patient receiving optimal heart failure therapy. Indeed, the definition of severe chronic kidney disease is an eGFR 15–29 mL/min/1.73 m2 for 3 mo or longer.7 The second is that potential heart transplant recipients with severe chronic renal disease but not yet requiring permanent renal replacement therapy should be considered for combined simultaneous heart and kidney transplantation (sHKTx) from the same donor. Although outcomes of pre-emptive sHKTx have been comparable to heart transplant alone in patients with preserved renal function, it removes a kidney from the deceased donor pool for dialysis-dependent patients awaiting kidney transplant alone.8 In this issue of the journal, Kumar et al report the findings of a more recent analysis of the UNOS database again looking at the impact of pretransplant eGFR measured at the time of transplant on mortality following isolated heart transplantation.9 The authors focused their analysis on 689 nondialysis patients with a pretransplant eGFR <30 mL/min/1.73 m2 who underwent heart transplantation between 2000 and 2015. The authors stratified the study population into 2 groups: those with an eGFR between 21 and 29 mL/min/1.73 m2 (n = 563) and those with an eGFR <20 mL/min/1.73 m2 (n = 126). The 1-, 5-, and 10-y survival for the entire cohort was excellent: 95.5%, 80.5%, and 64.4%. The overall incidence of ESKD at 1, 5, and 10 y were 1.5%, 9.5%, and 20%. Mortality and ESKD incidence was similar between the 2 groups. Furthermore, the majority of patients had improved renal function posttransplant. Diabetes was the only independent variable associated with higher risk of ESKD in patients with eGFR <30 mL/min/1.73 m2 who received an isolated heart transplant. The authors concluded that as progression to ESKD occurred in <10% of heart transplant recipients within 5 y of transplant, the majority of patients did not warrant sHKTx, even though they would have been eligible based on current consensus recommendations.6,8 The main limitation of their study and‚ indeed‚ of previous UNOS Database analyses is that the estimation of renal function before transplantation was based on a single measurement taken immediately pretransplant. Given that many heart transplant recipients are hemodynamically unstable with various degrees of acute kidney injury at the time of heart transplantation, the pretransplant eGFR likely underestimates the baseline renal function in these individuals. It is noteworthy that more than half of the recipients in this study were on intravenous inotropic or intra-aortic balloon pump support at the time of heart transplantation.9 Other limitations of the UNOS database include a lack of data on the trajectory of renal function while patients are on the waitlist and a lack of inclusion of other potentially important risk factors for ESKD‚ such as proteinuria and renal imaging. Assessment for sHKTx requires a comprehensive assessment by 2 transplant teams. The decision to list a patient for sHKTx in patients with ESKD who are not yet on dialysis is then based on an eGFR <30 mL/min/1.73 m2, taking into consideration results of other renal investigations and after the patient has been stabilized on optimal medical therapy. Hence, the eGFR at the time of listing rather than at the time of transplant would be expected to be a better predictor of posttransplant outcome. Surprisingly, based on UNOS Registry analysis‚ this does not appear to be the case.5 In the study by Kumar et al, an eGFR of <30 mL/min/1.73 m2 at the time of transplant listing was predictive of incident end-stage renal disease but not mortality after heart transplantation. At present‚ we lack a reliable indicator of what the trajectory of renal function will be following heart transplant alone in patients with severe chronic renal impairment. If we are to achieve equitable utilization of scarce donor organs, we need to develop better tools for assessing reversibility of renal impairment in the setting of advanced heart failure and for selecting those patients not yet on permanent dialysis who should undergo sHKTx.
No takes yet. Share an insight, caveat, or question.
Peter S. Macdonald (2022) conducted an editorial in Chronic heart failure with severe renal impairment (n=689). Pretransplant eGFR <20 mL/min/1.73 m2 vs. Pretransplant eGFR 21-29 mL/min/1.73 m2 was evaluated on Mortality and incident end-stage kidney disease (ESKD).
Synapse has enriched 10 related papers. Consider them for comparative context: